Drug Metabolism and Pharmacokinetics (DMPK)
At Frontage, our scientific staff applies state-of-the-art techniques and best-in-class approaches to generate data for critical milestones and decision-making during drug discovery and development. The highly trained and experienced scientific team provides broad and in-depth expertise/advice to clients on appropriate study designs, execution of studies, and interpretation of the data. We offer extensive drug metabolism and pharmacokinetic capabilities for new chemical entities and compounds in development. We provide rapid turnaround of high-quality key DMPK data sets to support critical decisions in advancing potential therapeutic agents for further development.
A range of capabilities and experience exist at Frontage to support discovery and development of drug candidates.
In Vitro ADME and In Vivo Studies
- In Vitro Services:
- In Vitro ADME Screening
- In Vitro ADME Development Studies
- In Vivo Services
Metabolite Syntheses and Radiolabel/Isotope Services
- Synthesis of stable isotopes for metabolism studies and as internal standards for GLP bioanalytical studies.
- Synthesis of metabolite standards (chemically or biologically).
QWBA Studies and Dosimetry
QWBA studies are designed to evaluate the time course of elimination for total radioactivity from tissues in animals. Tissue distribution data obtained from a QWBA study will be utilized to support regulatory submissions, discovery projects, and to provide dosimetry calculations required by regulatory authorities and institutional review boards prior to the administration of radiolabeled drugs to human research subjects.
Human Radiolabel Studies (hAME)
Comprehensive studies including in-life administration with radiolabeled compounds, sample collections, mass balance, pharmacokinetics of total radioactivity and test compound, and metabolite profiling in plasma, urine and feces. Studies are performed in collaboration with Frontage Clinical Services.